Scarica l'app Stockscreener
135.63
1.50%
-2.07
Dopo l'orario di chiusura:
135.63
Precedente Chiudi:
$137.70
Aprire:
$136.42
Volume 24 ore:
804.38K
Relative Volume:
0.49
Capitalizzazione di mercato:
$6.66B
Reddito:
$4.06B
Utile/perdita netta:
$413.08M
Rapporto P/E:
16.93
EPS:
8.01
Flusso di cassa netto:
$560.48M
1 W Prestazione:
-0.80%
1M Prestazione:
+15.64%
6M Prestazione:
-31.86%
1 anno Prestazione:
-35.33%
Intervallo 1D:
$134.08
$136.94
Intervallo di 1 settimana:
$134.08
$140.65
Portata 52W:
$91.86
$254.15
Charles River Laboratories International Inc Stock (CRL) Company Profile
Nome
Charles River Laboratories International Inc
Settore
Industria
Telefono
781-222-6000
Indirizzo
251 BALLARDVALE ST, WILMINGTON, MA
Confronta CRL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
135.63 | 6.72B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
402.82 | 148.60B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.90 | 132.07B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
513.36 | 40.34B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.92 | 30.82B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
140.33 | 23.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-23 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-05-08 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-03 | Aggiornamento | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Downgrade | UBS | Buy → Neutral |
| 2024-11-18 | Downgrade | CLSA | Hold → Underperform |
| 2024-11-07 | Aggiornamento | CLSA | Underperform → Hold |
| 2024-10-23 | Iniziato | CLSA | Underperform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Sell |
| 2024-10-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-01 | Downgrade | Citigroup | Neutral → Sell |
| 2024-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Downgrade | Argus | Buy → Hold |
| 2024-06-07 | Iniziato | Mizuho | Neutral |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-02-15 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-09-13 | Iniziato | TD Cowen | Market Perform |
| 2023-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2023-02-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-12 | Downgrade | Jefferies | Buy → Hold |
| 2022-09-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-08-04 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Iniziato | Guggenheim | Neutral |
| 2022-04-25 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-07 | Iniziato | Stephens | Overweight |
| 2022-02-17 | Reiterato | BofA Securities | Buy |
| 2022-02-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-17 | Reiterato | Deutsche Bank | Buy |
| 2022-02-17 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-17 | Reiterato | UBS | Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-07-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-05-13 | Aggiornamento | UBS | Neutral → Buy |
| 2020-04-21 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Buy |
| 2020-02-18 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Iniziato | SVB Leerink | Outperform |
| 2019-04-30 | Ripresa | Evercore ISI | Outperform |
| 2018-12-14 | Iniziato | Deutsche Bank | Buy |
| 2018-10-09 | Iniziato | UBS | Neutral |
| 2018-08-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Aggiornamento | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Charles River Laboratories International Inc Borsa (CRL) Ultime notizie
Charles River Laboratories International, Inc. (CRL): A Bull Case Theory - Insider Monkey
Do Wall Street Analysts Like Charles River Laboratories Stock? - MSN
Charles River surges after Q1 beat, guidance raise - MSN
Charles River Laboratories, CHDI Foundation Extend Collaboration - marketscreener.com
Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington’s Disease Research - BioSpace
Charles River Laboratories International Extend Drug Discovery Partnership With CHDI Foundation - marketscreener.com
Charles River Labs extends Huntington’s disease research pact By Investing.com - Investing.com India
Charles River (CRL) and CHDI Foundation Extend Partnership for H - GuruFocus
Charles River Labs extends Huntington’s disease research pact - Investing.com Australia
Charles River Laboratories (CRL) and CHDI Foundation Extend Multi-Decade Collaboration on Huntington’s Disease Research - StreetInsider
Redburn Upgrades Charles River Laboratories (CRL) to Buy, Cuts PT - MSN
Should You Continue to Hold Charles River Stock in Your Portfolio? - MSN
There's No Escaping Charles River Laboratories International, Inc.'s (NYSE:CRL) Muted Revenues Despite A 25% Share Price Rise - simplywall.st
Charles River Laboratories International, Inc. (CRL) Extends CEO's Employment Agreement - GuruFocus
Charles River (CRL) Upgraded to Buy Amid Strategic Developments | CRL Stock News - GuruFocus
Redburn raises Charles River Labs to buy, cuts price target to $182 - Investing.com Nigeria
Redburn raises Charles River Labs to buy, cuts price target to $182 By Investing.com - Investing.com South Africa
Charles River Laboratories International CEO James C. Foster's Employment Extended Until February 2027SEC Filing - marketscreener.com
Charles River Labs Extends CEO’s Term Amid Shareholder Meeting - TipRanks
This Waste Management Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
CRL Stock Upgraded to 'Buy' by Redburn Atlantic Despite PT Reduc - GuruFocus
CRL Stock Upgraded to 'Buy' by Redburn Atlantic Despite PT Reduction | CRL Stock News - GuruFocus
Charles River (CRL) Seen as Beneficiary of Potential Earnings Gr - GuruFocus
Charles River (CRL) Seen as Beneficiary of Potential Earnings Growth | CRL Stock News - GuruFocus
Redburn Atlantic Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $182 From $188 - marketscreener.com
Bioanalytical Testing Services Market Booming with Growth - openPR.com
Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know - FinancialContent
Charles River Laboratories (CRL): Leadership Change at Ginkgo Bi - GuruFocus
Charles River Laboratories (CRL): Leadership Change at Ginkgo Bioworks | CRL Stock News - GuruFocus
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Charles River Laboratories International Inc (CRL) Trading Down 3.98% on May 21 - GuruFocus
Drug Development Inputs & Services Stocks Q1 Results: Benchmarking Charles River Laboratories (NYSE:CRL) - FinancialContent
Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Rating of “Hold” by Brokerages - Defense World
Insider Sell: George Massaro Sells Shares of Charles River Labor - GuruFocus
Charles River Laboratories International (NYSE:CRL) Upgraded at TD Cowen - Defense World
Insider Sell: George Massaro Sells Shares of Charles River Laboratories International Inc (CRL) - GuruFocus
RNA Therapy Clinical Trials Market Top Companies StudyCharles - openPR.com
Charles River (CRL) Receives Upgrade and $179 Price Target | CRL Stock News - GuruFocus
We Think Charles River Laboratories International, Inc.'s (NYSE:CRL) CEO Compensation Package Needs To Be Put Under A Microscope - simplywall.st
Charles River (CRL) Upgraded to Buy Amid Potential Value Unlocki - GuruFocus
TD Cowen Upgrades Charles River Laboratories International to Buy From Hold, Adjusts PT to $179 From $105 - marketscreener.com
Unlocking Value: Strategic Divestitures and Market Leadership at Charles River Labs - TipRanks
Charles River Laboratories to Present at Bank of America Health Care Conference - BioSpace
Cell Banking Outsourcing Market: Executive Briefing & - openPR.com
Understanding Charles River (CRL) Reliance on International Revenue - Yahoo Finance
Human Microbiome Sequencing Market Top PlayersBaseclear - openPR.com
Charles river raises 2025 guidance with focus on NAMs and cost optimization - MSN
William Blair Has Bullish Forecast for CRL Q2 Earnings - Defense World
Charles River Laboratories International Inc Azioni (CRL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
1.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):